Items where authors include "Schwarz, C."

Article

Keating, C., Yonker, L.M., Vermeulen, F. et al. (320 more authors) (2025) Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. The Lancet Respiratory Medicine, 13 (3). pp. 256-271. ISSN 2213-2600

Simmonds, N.J., Southern, K.W., De Wachter, E. et al. (26 more authors) (2024) ECFS standards of care on CFTR-related disorders: Identification and care of the disorders. Journal of Cystic Fibrosis, 23 (4). pp. 590-602. ISSN 1569-1993

Burgel, P.-R., Ballmann, M., Drevinek, P. et al. (8 more authors) (2024) Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy. BMJ Open Respiratory Research, 11 (1). e002049. ISSN 2052-4439

Uluer, A.Z., MacGregor, G., Azevedo, P. et al. (103 more authors) (2023) Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. The Lancet Respiratory Medicine, 11 (6). pp. 550-562. ISSN 2213-2600

Mainz, J.G., Zagoya, C., Polte, L. et al. (12 more authors) (2023) Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score. Frontiers in Pharmacology, 14. 1207356. ISSN 1663-9812

Adam, J., Adamczyk, L., Agrawal, N. et al. (436 more authors) (2022) ATHENA detector proposal - a totally hermetic electron nucleus apparatus proposed for IP6 at the Electron-Ion Collider. Journal of Instrumentation. P10019. ISSN 1748-0221

Al Ghoul, H., Anassontzis, E. G., Austregesilo, A. et al. (114 more authors) (2017) Measurement of the beam asymmetry Σ for π0 and η photoproduction on the proton at Eγ=9 GeV. Physical Review C. 042201. ISSN 2469-9993

Proceedings Paper

Mainz, J.G., Zagoya, C., Polte, L. et al. (12 more authors) (2022) WS02.01 Abdominal symptoms significantly decline after 24 weeks of elexacaftor/tezacaftor/ivacaftor treatment: first results obtained with the cystic fibrosis-specific CFAbd-Score in Germany and the UK. In: Journal of Cystic Fibrosis. 45th European Cystic Fibrosis Conference, 08-11 Jun 2022, Rotterdam, The Netherlands. Elsevier .